These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6716396)

  • 61. Experimental procedure for estimating the dissociation constant of noncompetitive interactants. Part I.
    Orsetti M
    Boll Soc Ital Biol Sper; 1986 Jan; 62(1):51-7. PubMed ID: 3718726
    [No Abstract]   [Full Text] [Related]  

  • 62. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated?
    MacKay D
    J Pharm Pharmacol; 1978 May; 30(5):312-3. PubMed ID: 26747
    [No Abstract]   [Full Text] [Related]  

  • 63. Nutrients/non-nutrients and drug metabolism.
    Krishnaswamy K
    Drug Nutr Interact; 1985; 4(1-2):235-47. PubMed ID: 3908044
    [No Abstract]   [Full Text] [Related]  

  • 64. Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties.
    Huang G; Nimczick M; Decker M
    Arch Pharm (Weinheim); 2015 Aug; 348(8):531-40. PubMed ID: 25941009
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The ways of designing new-generation medicinal and biochemical agents by using ligand-receptor interactions for active membrane transport].
    Iurkevich AM; Shvets VI
    Vestn Ross Akad Med Nauk; 1999; (3):3-7. PubMed ID: 10222823
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An innovative method to study target protein-drug interactions by mass spectrometry.
    Müller MQ; de Koning LJ; Schmidt A; Ihling C; Syha Y; Rau O; Mechtler K; Schubert-Zsilavecz M; Sinz A
    J Med Chem; 2009 May; 52(9):2875-9. PubMed ID: 19379014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Experimental allergy as a model of pharmacological activity].
    Alonso de Florida F
    Bol Estud Med Biol; 1983; 32(7-8 Suppl 1):53-65. PubMed ID: 6100436
    [No Abstract]   [Full Text] [Related]  

  • 68. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cyclosporin A-cyclophilin complex formation. A model based on X-ray and NMR data.
    Spitzfaden C; Weber HP; Braun W; Kallen J; Wider G; Widmer H; Walkinshaw MD; Wüthrich K
    FEBS Lett; 1992 Apr; 300(3):291-300. PubMed ID: 1555658
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Receptors; from idea to reality].
    Ariëns EJ
    Ned Tijdschr Geneeskd; 1983 Jul; 127(28):1235-8. PubMed ID: 6310420
    [No Abstract]   [Full Text] [Related]  

  • 71. Macromolecule structure determination using NMR data and molecular simulation techniques.
    Olafson BD; Marusin JR; Ary ML
    Am Biotechnol Lab; 1990 Jun; 8(8):18-24. PubMed ID: 1366598
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fundamentals of drug design from a biophysical viewpoint.
    van Gunsteren WF; King PM; Mark AE
    Q Rev Biophys; 1994 Dec; 27(4):435-81. PubMed ID: 7784540
    [No Abstract]   [Full Text] [Related]  

  • 73. Simultaneous binding of drugs with different chemical structures to Ca2+-calmodulin: crystallographic and spectroscopic studies.
    Vertessy BG; Harmat V; Böcskei Z; Náray-Szabó G; Orosz F; Ovádi J
    Biochemistry; 1998 Nov; 37(44):15300-10. PubMed ID: 9799490
    [TBL] [Abstract][Full Text] [Related]  

  • 74. NMR fragment screening: Advantages and applications.
    Schade M
    IDrugs; 2006 Feb; 9(2):110-3. PubMed ID: 16523400
    [TBL] [Abstract][Full Text] [Related]  

  • 75. pA2 and receptor differentiation: a statistical analysis of competitive antagonism.
    Tallarida RJ; Cowan A; Adler MW
    Life Sci; 1979 Aug; 25(8):637-54. PubMed ID: 388133
    [No Abstract]   [Full Text] [Related]  

  • 76. Structural genomics and the metabolome: combining computational and NMR methods to identify target ligands.
    Parsons L; Orban J
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):62-8. PubMed ID: 14982149
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug metabolism and pharmacokinetics in malutrition.
    Krishnaswamy K
    Clin Pharmacokinet; 1978; 3(3):216-40. PubMed ID: 350472
    [No Abstract]   [Full Text] [Related]  

  • 78. Molecular recognition: models for drug design.
    Breckenridge RJ
    Experientia; 1991 Dec; 47(11-12):1148-61. PubMed ID: 1765127
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Pecularities of drug therapy in early childhood].
    Weingärtner L; Sitka U
    Z Arztl Fortbild (Jena); 1977 Apr; 71(8):366-71. PubMed ID: 878505
    [No Abstract]   [Full Text] [Related]  

  • 80. [Pharmacotherapy and aging].
    Platt D
    Internist (Berl); 1984 Aug; 25(8):491-500. PubMed ID: 6384115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.